ClinicalTrials.gg
CompletedNCT01307384Updated Sep 29, 2026

Zimmer Continuum Metal on Polyethylene (MoP) PostMarket Clinical Followup (PMCF) Study

An observational study in Avascular Necrosis, Osteoarthritis and Inflammatory Arthritis, sponsored by Zimmer Biomet. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Zimmer Biomet · Observational

How we know

Updated Sep 29, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
195
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Osteonecrosis by Zimmer Biomet — 3 open to participants now, 15 under way, none of them phase 3. Osteonecrosis · Zimmer Biomet.

Enrollment
11th of 41
195 · median 118
Started
2011
with 7 others
Observational
41 of 57
1 open now
Registered
19th of 57
by date

Among the 57 studies in Osteonecrosis by Zimmer Biomet, this one is the 11th largest by enrollment of the 41 observational ones that give a count, is one of 8 that started in 2011, is one of 41 observational ones, and was the 19th registered.

Osteonecrosis

287 studies on the registry are indexed under Osteonecrosis; 46 are open to participants now.

Browse Osteonecrosis studies →

Open to participants now

3 of the 57 studies in Osteonecrosis by Zimmer Biomet are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 23 Osteonecrosis studies recruiting now, 14 (61%) set no upper age limit and 4 (17%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Osteonecrosis by Zimmer Biomet, or all of them as a file.
02

Study summary

This is a prospective, multi-center, non-randomized, non-controlled study designed to obtain survival and outcome data on the Continuum Metal on Polyethylene Acetabular System when used in primary total hip arthroplasty.

Read the detailed description

The safety and performance of the Continuum Metal on Polyethylene Acetabular System will be confirmed by the assessment of survival and outcome data. Assessments will include standard scoring systems, radiographs and adverse event records. Data will be used to monitor pain, mobility, and survivorship of the Continuum Metal on Polyethylene Acetabular system in primary total hip arthroplasty. Metal ion (cobalt, chromium and titanium) and renal function (BUN, Creatinine and GFR) levels will be analyzed for a subset of the enrolled study subjects.

03

Conditions studied

  • Avascular Necrosis
  • Osteoarthritis
  • Inflammatory Arthritis
  • Post-traumatic Arthritis
  • Rheumatoid Arthritis

Keywords

  • Total Hip Arthroplasty
  • Total Hip Replacement (THR)
  • Primary Hip Arthroplasty
  • THA
  • THR
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients from surgeons medical practice who are candidates for primary hip arthroplasty.

The study population will be comprised of 300 males and females who require primary total hip arthroplasty. Subjects will be enrolled at up to 7 clinical sites. Subjects must be geographically accessible throughout the study and be willing and able to attend required follow-up appointments. Candidates who express interest in study participation will be offered informed consent, and eligibility will be determined based upon the inclusion/exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is 18 to 75 years of age, inclusive.
  • Patient is skeletally mature.
  • Patient qualifies for primary unilateral or bilateral (simultaneous or staged) total hip arthroplasty (THA) based on physical exam and medical history including the following:

    • Avascular necrosis (AVN)
    • Osteoarthritis
    • Inflammatory arthritis (i.e., Rheumatoid arthritis)
    • Post-traumatic arthritis
  • Patient has no history of previous prosthetic replacement device of any type, including surface replacement arthroplasty, endoprosthesis, etc. of the affected hip joint(s).
  • Patient has moderate, marked or disabling pain.
  • Patient is willing and able to provide written .
  • Patient is willing and able to cooperate in the required post-operative therapy.
  • Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.
  • Patient has participated in the Informed Consent process and has signed the IRB approved informed consent.

Exclusion criteria

Exclusion Criteria:

  • The patient is:

    • A prisoner
    • Mentally incompetent or unable to understand what participation in the study entails
    • A known alcohol or drug abuser
    • Anticipated to be non-compliant
  • The patient has a neuromuscular disorder, vascular disorder or other conditions that could contribute to prosthesis instability, prosthesis fixation failure or complications in postoperative care.
  • The patient has a neurologic condition in the ipsilateral or contralateral limb which affects lower limb function.
  • The patient has a diagnosed systemic disease that could affect his/her safety or the study outcome.
  • The patient is known to be pregnant.
  • The patient is unwilling or unable to give consent or to comply with the follow-up program.
  • The patient has received an drug or device within the previous 6 months.
  • The patient has an active or latent infection in or about the affected hip joint or an infection distant from the hip joint that may spread to the hip hematogenously.
  • The patient has insufficient bone stock to fix the component. Insufficient bone stock exists in the presence of metabolic bone disease (i.e., osteoporosis), cancer, and radiation. Note: Dual Energy X-ray Absorptiometry (DEXA) may be used to assess the presence of adequate bone stock.
  • The patient has osteoradionecrosis in the affected hip joint.
  • The patient has a known sensitivity or allergic reaction to one or more of the implanted materials.
  • The patient has known local bone tumors and/or cysts in the operative hip.
  • The patient has a (BMI) > 40.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
195 participants (actual)
Patient registry
No

Groups and cohorts

  • Continuum Acetabular System

    Patients receiving primary hip arthroplasty using the Continuum Metal on Polyethylene Acetabular System

    Device: Continuum Metal on Polyethylene Acetabular System

Interventions

  • DeviceContinuum Metal on Polyethylene Acetabular System

    Used in primary hip arthroplasty

    Also known as: Total Hip Replacement, Total Hip Arthroplasty, Primary Hip

06

What researchers measure

Primary outcomes

  1. Survivorship

    Based on removal or intended removal of the device and determined using the Kaplan-Meier method.

    Time frame: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

  2. Safety / Adverse Events

    Safety will be evaluated by monitoring the frequency and incidence of device related adverse events or unanticipated adverse device effects in investigational subjects.

    Time frame: Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Secondary outcomes

  1. Pain and Function / HHS

    Pain and function will be measured using the Harris Hip Score self assessment.

    Time frame: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

  2. Pain and Function / OHS

    Pain and function will be measured using the Oxford Hip Score self assessment.

    Time frame: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

  3. Health Status / SF-12

    Health status will be measured using the SF-12 self assessment.

    Time frame: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

  4. Health Status / Radiographic Parameters

    X-rays will be evaluated for acetabular cup angle, acetabular cup migration, femoral stem position, femoral stem subsidence and femoral stem shift.

    Time frame: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Other outcomes

  1. Metal Ion / Cobalt

    Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

    Time frame: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

  2. Metal Ion / Chromium

    Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

    Time frame: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

  3. Metal Ion / Titanium

    Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

    Time frame: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

  4. Renal Function / BUN

    Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

    Time frame: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

  5. Renal Function / Creatinine

    Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

    Time frame: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

  6. Renal Function / GFR

    Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

    Time frame: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

07

Study locations

2 sites
  • Sah Orthopaedic Associates
    Fremont, California 94538, United States
  • Denver Health Medical Center
    Denver, Colorado 80204, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Jul 2026, 183 months.

Of 59 observational studies under Osteonecrosis, half reached primary completion within 141 months of starting (the median), counting those still running; a quarter within 93 and three quarters within 184. This study's 183 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Dec 2027 → Jul 2026 and completion Dec 2027 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2011
First posted
Mar 2, 2011
StartActual
Mar 29, 2011
Primary completionActual
Jul 17, 2026was Dec 2027
CompletionActual
Jul 17, 2026was Dec 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 29, 2026
Primary completion
Dec 2027→Jul 17, 2026 (actual)
Sep 29, 2026
Study completion
Dec 2027→Jul 17, 2026 (actual)
Sep 29, 2026
Enrollment
165→195
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Active, not recruiting→Completed
    Primary completion Dec 2027→Jul 17, 2026 (now actual)
    Study completion Dec 2027→Jul 17, 2026 (now actual)
    Enrollment 165→195
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01307384
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Mar 2, 2011
Start date
Mar 29, 2011
Primary completion
Jul 17, 2026
Completion
Jul 17, 2026
Last update
Sep 29, 2026

Study contacts

Hillary Overholser
study director · Zimmer Biomet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion